{"id":1358,"date":"2016-04-22T16:15:15","date_gmt":"2016-04-22T14:15:15","guid":{"rendered":"https:\/\/www.lungcancergroup.de\/en\/?post_type=project&#038;p=1358"},"modified":"2016-04-22T16:15:15","modified_gmt":"2016-04-22T14:15:15","slug":"activity-safety-ceritinib-patients-alk-rearranged-non-small-cell-lung-cancer-ascend-1-updated-results-multicentre-open-label-phase-1-trial","status":"publish","type":"project","link":"https:\/\/www.lungcancergroup.de\/en\/project\/activity-safety-ceritinib-patients-alk-rearranged-non-small-cell-lung-cancer-ascend-1-updated-results-multicentre-open-label-phase-1-trial\/","title":{"rendered":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial"},"content":{"rendered":"<p>[et_pb_section admin_label=&#8221;section&#8221;][et_pb_row admin_label=&#8221;row&#8221;][et_pb_column type=&#8221;4_4&#8243;][et_pb_text admin_label=&#8221;Projekttitel&#8221; background_layout=&#8221;light&#8221; text_orientation=&#8221;left&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221;]<\/p>\n<h4><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26973324\">Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial<\/a><\/h4>\n<p>[\/et_pb_text][et_pb_text admin_label=&#8221;Autoren&#8221; background_layout=&#8221;light&#8221; text_orientation=&#8221;left&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221;]<\/p>\n<p>Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A8, Shaw AT<\/p>\n<p>[\/et_pb_text][et_pb_text admin_label=&#8221;Journal+Ver\u00f6ffentlichung&#8221; background_layout=&#8221;light&#8221; text_orientation=&#8221;left&#8221; use_border_color=&#8221;off&#8221; border_color=&#8221;#ffffff&#8221; border_style=&#8221;solid&#8221;]<\/p>\n<p>Journal: Lancet Oncol.<br \/>\nPublished: March 6th, 2016<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Journal: Lancet Oncol.<br \/>\nPublished: March 6th, 2016<\/p>\n","protected":false},"author":19,"featured_media":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"project_category":[45],"project_tag":[],"class_list":["post-1358","project","type-project","status-publish","hentry","project_category-2016-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial - Lung Cancer Group Cologne<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lungcancergroup.de\/en\/project\/activity-safety-ceritinib-patients-alk-rearranged-non-small-cell-lung-cancer-ascend-1-updated-results-multicentre-open-label-phase-1-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial - Lung Cancer Group Cologne\" \/>\n<meta property=\"og:description\" content=\"Journal: Lancet Oncol. Published: March 6th, 2016\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lungcancergroup.de\/en\/project\/activity-safety-ceritinib-patients-alk-rearranged-non-small-cell-lung-cancer-ascend-1-updated-results-multicentre-open-label-phase-1-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Lung Cancer Group Cologne\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.lungcancergroup.de\/en\/project\/activity-safety-ceritinib-patients-alk-rearranged-non-small-cell-lung-cancer-ascend-1-updated-results-multicentre-open-label-phase-1-trial\/\",\"url\":\"https:\/\/www.lungcancergroup.de\/en\/project\/activity-safety-ceritinib-patients-alk-rearranged-non-small-cell-lung-cancer-ascend-1-updated-results-multicentre-open-label-phase-1-trial\/\",\"name\":\"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial - Lung Cancer Group Cologne\",\"isPartOf\":{\"@id\":\"https:\/\/www.lungcancergroup.de\/en\/#website\"},\"datePublished\":\"2016-04-22T14:15:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.lungcancergroup.de\/en\/project\/activity-safety-ceritinib-patients-alk-rearranged-non-small-cell-lung-cancer-ascend-1-updated-results-multicentre-open-label-phase-1-trial\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.lungcancergroup.de\/en\/project\/activity-safety-ceritinib-patients-alk-rearranged-non-small-cell-lung-cancer-ascend-1-updated-results-multicentre-open-label-phase-1-trial\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.lungcancergroup.de\/en\/project\/activity-safety-ceritinib-patients-alk-rearranged-non-small-cell-lung-cancer-ascend-1-updated-results-multicentre-open-label-phase-1-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.lungcancergroup.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Projects\",\"item\":\"https:\/\/www.lungcancergroup.de\/en\/project\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.lungcancergroup.de\/en\/#website\",\"url\":\"https:\/\/www.lungcancergroup.de\/en\/\",\"name\":\"Lung Cancer Group Cologne\",\"description\":\"Lungenkrebs Studiengruppe K\u00f6ln\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.lungcancergroup.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial - Lung Cancer Group Cologne","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lungcancergroup.de\/en\/project\/activity-safety-ceritinib-patients-alk-rearranged-non-small-cell-lung-cancer-ascend-1-updated-results-multicentre-open-label-phase-1-trial\/","og_locale":"en_US","og_type":"article","og_title":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial - Lung Cancer Group Cologne","og_description":"Journal: Lancet Oncol. Published: March 6th, 2016","og_url":"https:\/\/www.lungcancergroup.de\/en\/project\/activity-safety-ceritinib-patients-alk-rearranged-non-small-cell-lung-cancer-ascend-1-updated-results-multicentre-open-label-phase-1-trial\/","og_site_name":"Lung Cancer Group Cologne","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.lungcancergroup.de\/en\/project\/activity-safety-ceritinib-patients-alk-rearranged-non-small-cell-lung-cancer-ascend-1-updated-results-multicentre-open-label-phase-1-trial\/","url":"https:\/\/www.lungcancergroup.de\/en\/project\/activity-safety-ceritinib-patients-alk-rearranged-non-small-cell-lung-cancer-ascend-1-updated-results-multicentre-open-label-phase-1-trial\/","name":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial - Lung Cancer Group Cologne","isPartOf":{"@id":"https:\/\/www.lungcancergroup.de\/en\/#website"},"datePublished":"2016-04-22T14:15:15+00:00","breadcrumb":{"@id":"https:\/\/www.lungcancergroup.de\/en\/project\/activity-safety-ceritinib-patients-alk-rearranged-non-small-cell-lung-cancer-ascend-1-updated-results-multicentre-open-label-phase-1-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lungcancergroup.de\/en\/project\/activity-safety-ceritinib-patients-alk-rearranged-non-small-cell-lung-cancer-ascend-1-updated-results-multicentre-open-label-phase-1-trial\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.lungcancergroup.de\/en\/project\/activity-safety-ceritinib-patients-alk-rearranged-non-small-cell-lung-cancer-ascend-1-updated-results-multicentre-open-label-phase-1-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.lungcancergroup.de\/en\/"},{"@type":"ListItem","position":2,"name":"Projects","item":"https:\/\/www.lungcancergroup.de\/en\/project\/"},{"@type":"ListItem","position":3,"name":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial"}]},{"@type":"WebSite","@id":"https:\/\/www.lungcancergroup.de\/en\/#website","url":"https:\/\/www.lungcancergroup.de\/en\/","name":"Lung Cancer Group Cologne","description":"Lungenkrebs Studiengruppe K\u00f6ln","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lungcancergroup.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/project\/1358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/types\/project"}],"author":[{"embeddable":true,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/comments?post=1358"}],"version-history":[{"count":1,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/project\/1358\/revisions"}],"predecessor-version":[{"id":1359,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/project\/1358\/revisions\/1359"}],"wp:attachment":[{"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/media?parent=1358"}],"wp:term":[{"taxonomy":"project_category","embeddable":true,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/project_category?post=1358"},{"taxonomy":"project_tag","embeddable":true,"href":"https:\/\/www.lungcancergroup.de\/en\/wp-json\/wp\/v2\/project_tag?post=1358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}